Why the study?
Does ezetimibe added to statin therapy improve cardiovascular outcomes and lower LDL cholesterol in patients after acute coronary syndromes?
Does ezetimibe added to statin therapy improve cardiovascular outcomes and lower LDL cholesterol in patients after acute coronary syndromes?
Adding ezetimibe to statin therapy after acute coronary syndromes lowers LDL cholesterol below previous targets and provides additional cardiovascular benefit.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Collectively, this is not a story about bad drugs or bad guidelines. It’s a story about a broken system of delivery.”
Supports adding ezetimibe to statins post-ACS; extends LDL-lowering benefit to lower achieved levels.
When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes. Moreover, lowering LDL cholesterol to levels below previous targets provided additional benefit. (Funded by Merck; IMPROVE-IT ClinicalTrials.gov number, NCT00202878.).
No takes yet. Share an insight, caveat, or question.
Cannon et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: